NCT02719574 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 31
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 153
- group Id
- BG010
- value
- 18
- group Id
- BG011
- value
- 5
- units
- Participants
- groups
- description
- Participants with AML or MDS received single agent of FT-2102 100 mg orally QD in 28-day cycles until MTD or MED achieved.
- id
- BG000
- title
- Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)
- description
- Participants with AML or MDS received single agent of FT-2102 150 mg orally QD in 28-day cycles until MTD or MED achieved.
- id
- BG001
- title
- Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)
- description
- Participants with AML or MDS received single agent of FT-2102 150 mg orally BID in 28-day cycles until MTD or MED achieved.
- id
- BG002
- title
- Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)
- description
- Participants with AML or MDS received single agent of FT-2102 300 mg orally QD in 28-day cycles until MTD or MED achieved.
- id
- BG003
- title
- Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)
- description
- Participants with AML or MDS received combination therapy (FT-2102 150 mg QD and azacitidine administered at the dose of 75 mg/m\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.
- id
- BG004
- title
- Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)
- description
- Participants with AML or MDS received combination therapy (FT-2102 150 mg BID and azacitidine administered at the dose of 75 mg/m\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.
- id
- BG005
- title
- Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)
- description
- Participants with AML or MDS received single agent of FT-2102 150 mg orally BID in 28-day cycles until MTD or MED achieved.
- id
- BG006
- title
- Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)
- description
- Participants with AML or MDS received combination therapy (FT-2102 150 mg BID and azacitidine administered at the dose of 75 mg/m\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.
- id
- BG007
- title
- Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)
- description
- Participants with AML harboring IDH1 mutation received FT-2102 150 mg BID in combination with LDAC administered at the dose of 20 mg BID SC for 10 days every 28-day cycle until treatment discontinuation.
- id
- BG008
- title
- Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)
- description
- Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
- id
- BG009
- title
- Phase 2: Cohort 1; FT-2102 (Single Agent)
- description
- Participants with AML in morphologic CR/CRi after prior therapy with residual IDH1-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
- id
- BG010
- title
- Phase 2: Cohort 2; FT-2102 (Single Agent)
- description
- Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
- id
- BG011
- title
- Phase 2: Cohort 3; FT-2102 (Single Agent)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 37
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 1
- title
- <65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 68
- group Id
- BG010
- value
- 11
- group Id
- BG011
- value
- 3
- title
- 65 - <75 years
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 48
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 1
- title
- >=75 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 74
- group Id
- BG010
- value
- 6
- group Id
- BG011
- value
- 2
- title
- Female
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 17
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 79
- group Id
- BG010
- value
- 12
- group Id
- BG011
- value
- 3
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 19
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 71
- group Id
- BG010
- value
- 10
- group Id
- BG011
- value
- 4
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 16
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 56
- group Id
- BG010
- value
- 7
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Full Analysis Set (FAS) included all the participants who were enrolled in the study and have received at least one dose of FT-2102.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 9
- group Id
- BG007
- value
- 31
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 153
- group Id
- BG010
- value
- 18
- group Id
- BG011
- value
- 5
- units
- Participants
- groups
- description
- Participants with AML or MDS received single agent of FT-2102 100 mg orally QD in 28-day cycles until MTD or MED achieved.
- id
- BG000
- title
- Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation)
- description
- Participants with AML or MDS received single agent of FT-2102 150 mg orally QD in 28-day cycles until MTD or MED achieved.
- id
- BG001
- title
- Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation)
- description
- Participants with AML or MDS received single agent of FT-2102 150 mg orally BID in 28-day cycles until MTD or MED achieved.
- id
- BG002
- title
- Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation)
- description
- Participants with AML or MDS received single agent of FT-2102 300 mg orally QD in 28-day cycles until MTD or MED achieved.
- id
- BG003
- title
- Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation)
- description
- Participants with AML or MDS received combination therapy (FT-2102 150 mg QD and azacitidine administered at the dose of 75 mg/m\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.
- id
- BG004
- title
- Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation)
- description
- Participants with AML or MDS received combination therapy (FT-2102 150 mg BID and azacitidine administered at the dose of 75 mg/m\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.
- id
- BG005
- title
- Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation)
- description
- Participants with AML or MDS received single agent of FT-2102 150 mg orally BID in 28-day cycles until MTD or MED achieved.
- id
- BG006
- title
- Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion)
- description
- Participants with AML or MDS received combination therapy (FT-2102 150 mg BID and azacitidine administered at the dose of 75 mg/m\^2 for 7 days IV/SC per every 28-day cycle) until treatment discontinuation.
- id
- BG007
- title
- Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion)
- description
- Participants with AML harboring IDH1 mutation received FT-2102 150 mg BID in combination with LDAC administered at the dose of 20 mg BID SC for 10 days every 28-day cycle until treatment discontinuation.
- id
- BG008
- title
- Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion)
- description
- Participants with R/R AML received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
- id
- BG009
- title
- Phase 2: Cohort 1; FT-2102 (Single Agent)
- description
- Participants with AML in morphologic CR/CRi after prior therapy with residual IDH1-R132 mutation were received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
- id
- BG010
- title
- Phase 2: Cohort 2; FT-2102 (Single Agent)
- description
- Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.
- id
- BG011
- title
- Phase 2: Cohort 3; FT-2102 (Single Agent)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 37
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 1
- title
- <65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 68
- group Id
- BG010
- value
- 11
- group Id
- BG011
- value
- 3
- title
- 65 - <75 years
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 48
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 1
- title
- >=75 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 14
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 74
- group Id
- BG010
- value
- 6
- group Id
- BG011
- value
- 2
- title
- Female
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 17
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 79
- group Id
- BG010
- value
- 12
- group Id
- BG011
- value
- 3
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 5
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 19
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 71
- group Id
- BG010
- value
- 10
- group Id
- BG011
- value
- 4
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 16
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 7
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 56
- group Id
- BG010
- value
- 7
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Full Analysis Set (FAS) included all the participants who were enrolled in the study and have received at least one dose of FT-2102.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle